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Abstract Like for all aurora-A kinases, the Xenopus pEg2
kinase level peaks in G2/M and is hardly detectable in G1 cells,
suggesting that the protein is degraded upon exit from mitosis as
reported for the human aurora-A kinase. We identified for the
first time a sequence RxxL in the C-terminal end of the kinase
catalytic domain. Mutation of this sequence RxxL to RxxI
suppresses the ubiquitination of the protein as well as its
degradation. The sequence RxxL corresponding to the pEg2
functional destruction box has been conserved throughout
evolution in all aurora kinases including aurora-A, -B and
-C. ß 2001 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
The mitotic aurora-A kinase is an oncogene, and overex-
pression detected in tumour cells is usually associated with the
presence of the 20q13 amplicon which comprises the kinase
gene [1,2]. However in few cases aurora-A overexpression is
detected without 20q13 ampli¢cation indicating that other
mechanisms might be involved in aurora-A overexpression.
One of them could be an abnormal stability of the protein.
Many proteins involved in mitosis must be inactivated or
degraded when the cell enters the following G1 phase of the
cell cycle. A dedicated degradation machinery known as the
APC/C (anaphase promoting complex/cyclosome) identi¢es
proteins previously ubiquitinated to be eliminated. Two major
pathways have been identi¢ed so far depending on two di¡er-
ent APC/C activators, Cdc20 and Cdh1 [3]. Although both
pathways are active during somatic cell cycle, the Cdh1 path-
way is absent during Xenopus early embryogenesis [4]. Pro-
teins targeted by these degradation pathways must possess a
destruction box recognised by the degradation machinery.
Two di¡erent sequences have been described: a D-box and
a KEN-box. The D-box contains two invariable conserved
residues, an arginine and a lysine, separated by two amino
acids [5]. The minimal required sequence RxxL is generally
localised in the N-terminus domain of the protein [5,6]. The
KEN-box which stands for a stretch of lysine/glutamic acid/
asparagine residues could be functional in any part of the
protein [7].
Human aurora-A has been found to be associated with the
APC/C [8], but although the kinase is ubiquitinated in vivo
and degraded through a mechanism sensitive to APC/C inhib-
itors, no functional destruction box has been identi¢ed yet
[9,10]. We report here the identi¢cation of a functional deg-
radation box in the Xenopus aurora-A kinase
2. Materials and methods
2.1. Reagents
Monoclonal antibodies 1C1 detect both the histidine-tagged and the
endogenous pEg2 whereas 6E3 detects only the histidine-tagged pEg2
[11,12].
2.2. Cell culture
Xenopus XL2 cell extracts were prepared from G1 synchronised
cells as described by Bastians et al. [13,14]. The cells were harvested,
incubated on ice for 20 min and lysed by soni¢cation at 4‡C and
cellular debris was removed by centrifugation at 14 000Ug for 30
min. The cell lysate was then collected, aliquoted, and frozen in liquid
nitrogen to be stored at 380‡C.
2.3. Recombinant proteins
pEg2 coding sequence was inserted in the bacterial expression vec-
tor pET21 (Novagen) as previously described [11]. The cyclin-like
destruction boxes were deleted by restriction enzyme digestions, and
the deleted fragment was replaced by a short DNA fragment contain-
ing an internal BamHI site to control the construction. This fragment
was obtained by hybridisation of two oligonucleotides. Deletion of
D1-box was obtained by digestion of pET21-pEg2 by BsrGI/EcoRI,
deletion of D2 by EcoRI/XhoI and deletion of D1/D2-boxes by BsrGI/
XhoI. D1-box was replaced by 5P-GTACACCGGATCCG-3P hybrid-
ised with 5P-AATTCGGATCCGGT-3P, D2 by 5P-AATTCGGA-
TCCC-3P hybridised with 5P-TCGAGGGATCCG-3P, D1/D2-boxes
by 5P-GTACACCGGTCCC-3P hybridised with 5P-TCGAGGG-
ACCGGT-3P. Deletion of the KEN-box in the N-terminal domain
was obtained by PCR reaction on the pET21-pEg2 vector. The two
primers used were 5P-AAG GCT AGC CAC AAG CCT TC-3P con-
taining a NheI site (underlined) and 5P-GGA GAT CTC GAG TTG
GGC GGC TGG AAG GGG-3P containing a XhoI site (underlined).
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The PCR product was directly cloned in pGEMT (Promega), and
transferred in pET21 by double NheI/XhoI digestion/ligation. All his-
tidine-tagged recombinant proteins were puri¢ed from BL21(DE3)-
pLysS by Ni-NTA-agarose a⁄nity chromatography following the
manufacturer’s instructions (Qiagen S.A.). All the puri¢ed proteins
proved soluble and were conserved in 50% glycerol solution at 320‡C.
2.4. Western blot analysis
After electrophoresis and transfer onto nitrocellulose membrane
(Amersham Pharmacia Biotech) by standard methods, the membranes
were blocked in TBST (20 mM Tris, pH 7.6, 137 mM NaCl, 0.1%
Tween) containing 5% skimmed milk for 2 h at 4‡C. The membranes
were incubated with speci¢c monoclonal antibodies for 1 h at 4‡C in
TBST containing 2.5% skimmed milk. After washing, the membranes
were then incubated with peroxidase-conjugated secondary antibody
(Sigma Chemicals). The immunocomplexes were revealed using per-
oxidase chemoluminescent substrates according to the manufacturer’s
instructions (NEN Life Sciences) and analysed on a FluoroImager
(Molecular Dynamics).
2.5. In vitro degradation assay
2 Wl of thawed cell extract was supplemented with an ATP regen-
erating system (1.5 mM ATP, 40 mM phospho-creatine, 80 Wg/ml
creatine kinase from Sigma Chemicals) and incubated with the re-
combinant puri¢ed protein in 7.4 mM HEPES pH 7.4, 5 mM KCl,
1.5 mM MgCl2, 1 mM dithiothreitol. The amount of recombinant
protein added to the extract never exceeded the amount of endoge-
nous pEg2 to avoid any saturation of the degradation machinery. The
reaction was incubated at 30‡C and aliquots were taken at various
time points (as indicated). Protein degradation products were sepa-
rated by 12.5% SDS^polyacrylamide gel electrophoresis, transferred
on nitrocellulose membrane, detected by Western blot using anti-pEg2
antibody and chemoluminescence and quanti¢ed using Image Quant
software. Inhibition of the 26S proteasome was achieved by incubat-
ing the cell extract with 40 WM ALLN (acetyl-leucyl-leucyl-norleuci-
nal) (Calbiochem, San Diego, CA, USA) prior to use in a degradation
assay.
3. Results and discussion
We identi¢ed three potential destruction boxes in the Xe-
nopus aurora-A kinase pEg2. Two RxxL D-boxes (D1 and D2)
and one KEN-box. The D1-box is located in the activation
loop of the kinase catalytic domain and the xx residues in the
sequence RxxL are two threonine residues, one of them being
an activating threonine when phosphorylated [1]. The D2-box
and the KEN-box have potentially interesting positions be-
cause of their accessibility respectively in the C-terminal end
(positions 6^8 in the wild-type protein) and the N-terminal
end of the protein (positions 378^381 in the wild-type pro-
tein).
We have analysed the function of these three potential de-
struction boxes in an in vitro degradation assay [14] using
recombinant histidine-tagged kinase pEg2 and various deleted
versions of pEg2: v(D1), v(D2), v(D1/D2) and v(KEN) (Fig.
1a,b). Upon incubation in the extract 40% of the recombinant
full length pEg2 was degraded within the ¢rst 30 min (Fig. 2a,
¢rst panel, and Fig. 2b). pEg2 was stabilised when the reac-
tion was performed in the presence of the proteasome inhib-
itor ALLN (Fig. 2a, ¢rst and second panels). The D1-box-
deleted recombinant protein was also rapidly degraded, 90%
after 30 min of incubation, and the degradation was also
inhibited by ALLN (Fig. 2a, fourth and ¢fth panels). In con-
trast, 75% of the D2-box-deleted protein remained after 120
min of incubation, indicating that the D2-box was functional
in our assay (Fig. 2a, sixth panel, and Fig. 2b). The deletion
of the two boxes D1 and D2 completely stabilised the protein
(Fig. 2a, last panel, and Fig. 2b). The KEN-box-deleted re-
combinant protein behaved just like the full length pEg2, in-
dicating that this destruction box was not functional in our
assay (Fig. 2a, third panel).
If one considers the aurora-A kinase family, the KEN-box
is not present in the Caenorhabditis elegans aurora-A kinase
sequences [16]. Additionally the second pEg2 cDNA version
(Xenopus laevis is tetraploid) (GenBank accession number
Z17207) does not contain any KEN-box. This should be a
strong argument against a function of the KEN-box sequence
in the degradation of the protein.
Giving the fact that the deletion of the D2-box had the most
dramatic e¡ect on the stability of the protein we compared the
C-terminal domain sequences of all aurora kinase catalytic
domains (Fig. 3a). An alignment of the sequences revealed
that a RxxL sequence is indeed found not only in every
aurora-A sequence but in all the aurora kinases identi¢ed
including aurora-B and aurora-C (Fig. 3a). The destruction
box is invariably found in the C-terminal end of the catalytic
domain of the kinase just downstream the kinase subdomain
11 (HxW) [17].
We then changed the leucine residue in the pEg2 D2-box
sequence RxxL by an isoleucine residue (Fig. 3b). A histidine-
tagged recombinant protein carrying this point mutation was
produced in Escherichia coli, puri¢ed and used in the degra-
dation assay (Fig. 3c) and in a ubiquitination assay (Fig. 3d).
Like the deletion of the D2-box the point mutation L/I in the
D2-box stabilised the pEg2 kinase.
Two previous papers have reported the ubiquitination of
the kinase [9,10]. Only the level of ubiquitination was reported
to be destruction box dependent, without any correlation with
the degradation of the protein. Giving the fact that aurora-A
Fig. 1. Deletions of potential destruction boxes in pEg2. a: Sche-
matic of recombinant pEg2 proteins used in the degradation assays
(see Section 2). b: The quality of the preparation was controlled by
Western blot using 1C1 monoclonal antibody (dilution 1:200). Lane
1: wild-type pEg2; lane 2: v(KEN); lane 3: v(D1); lane 4: v(D2);
lane 5: v(D1/D2).
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has already been demonstrated to be ubiquitinated we ana-
lysed the e¡ect of the D2-box L/I point mutation in the ca-
pacity of pEg2 to be ubiquitinated. The ubiquitination reac-
tion was performed with in vitro translated pEg2 in
metaphase-arrested Xenopus egg extract in the presence of
ubiquitin aldehyde which prevented hydrolysis of ubiquitin
residues by isopeptidases. Although the presence of the CSF
extract was not absolutely required for the ubiquitination its
presence stimulated the reaction (compare Fig. 3d, lanes 1 and
4). Nevertheless pEg2 was not ubiquitinated when the incu-
bation was carried out in the absence of ubiquitin aldehyde
and methylated ubiquitin (Fig. 3d, lane 2) or in vitro mock
translation (Fig. 3d, lane 3). In contrast, when ubiquitin was
added readily to pEg2 incubated in the egg extract, ubiquiti-
nated pEg2 conjugates were generated (Fig. 3d, lane 1). We
did not detect any ubiquitination of the D2-box L/I mutant
indicating that the sequence is recognised by the ubiquitina-
tion machinery or that the ubiquitination occurs at a much
lesser extent. The D2 destruction box seems to target the
ubiquitination of the protein as well as the degradation.
We demonstrate here in contradiction with what has been
previously reported for the human aurora-A [9] that the Xe-
nopus aurora-A contains a functional destruction box RxxL
which sequence and position have been conserved from yeast
to human. This sequence when deleted stabilised the Xenopus
aurora-A protein. Another RxxL sequence (D1) located in the
activation loop of the kinase might be partially functional in
our degradation assay. The Xenopus aurora-A kinase is totally
insensitive to degradation when the two RxxL (D1- and D2-
boxes) are deleted. There are at least three interpretations of
this result. (i) The D1-box sequence might also be an aurora-A
functional destruction box which is unlikely to be the case
because the sequence is not found in the mouse aurora-A
kinase [16]. (ii) The D1-box might become functional only
when the D2-box is deleted (e.g. in an arti¢cial situation),
‘mother nature always ¢nds a way!’. (iii) In the Xenopus
Fig. 3. Degradation and ubiquitination of L/I D2-box-mutated
pEg2. a: The sequence that corresponds to the pEg2 D2-box was
aligned with the D-box (RxxL) sequence of all aurora (-A, -B and
-C) kinases from yeast to human. b: Point mutation of pEg2 D2-
box, the leucine residue of the sequence RxxL was changed to an
isoleucine residue. c: Degradation kinetics of the L/I D2-box-mu-
tated pEg2. A point-mutated L/I D2-box histidine-tagged recombi-
nant pEg2 protein was prepared from E. coli and its stability tested
in a degradation assay (same condition as in Fig. 2). d: In vitro
translated pEg2 was incubated in the presence of metaphase-arrested
Xenopus egg extracts [15] in the presence of ubiquitin aldehyde and
methylated ubiquitin and immunodetected using the 6E3 monoclo-
nal antibody [12] (lane 1). In lane 2, the reaction was carried out
without ubiquitin aldehyde and methylated ubiquitin, and in lane 3
without in vitro translated pEg2. The ubiquitination of the point-
mutated L/I D2-box is shown in lane 5. The reaction mixtures were
separated on a 12% SDS^polyacrylamide gel and transferred to ni-
trocellulose. pEg2 was immunodetected using the monoclonal anti-
body 1C1 (dilution 1:500).
Fig. 2. pEg2 possesses a functional destruction box. Degradation ki-
netics of the various recombinant pEg2 proteins containing potential
destruction box deletions were performed in XL2 cell extracts pre-
pared from G1 synchronised cells [13]. The reaction was incubated
at 30‡C. The speci¢city of the degradation was controlled by addi-
tion of the APC/C inhibitor ALLN. a: Reaction products were sep-
arated by 12.5% SDS^polyacrylamide gel electrophoresis and ana-
lysed by Western blot using the 1C1 monoclonal antibody (1:200).
Aliquots of the reaction were taken at 0 (lane 1), 15 (lane 2), 30
(lane 3) and 120 min (lane 4). b: The Western blots were quanti¢ed
with Image Quant and the amount of protein detected at various
time points was expressed as a percentage of the protein detected at
t = 0 min (input).
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aurora-A kinase this D1-box sequence, RTTL, comprised the
threonine that when phosphorylated activates the kinase [1]. A
recent report has implicated a phosphorylation of the aurora-
A kinase as a prerequisite to its degradation [10], a residue in
this D1-box might be involved in this mechanism. Also one
can notice in our degradation assay that most of the recombi-
nant proteins added to the extract shifted before degradation.
This is particularly true for the D1/D2-boxes-deleted mutant
(that lacks the activating threonine residue). Nevertheless a
phosphorylation of the proteins seems to occur prior to deg-
radation, the relationship between this phosphorylation and
the degradation is currently being investigated. But the main
point is that there is no doubt about the existence of a func-
tional destruction box in the Xenopus aurora-A kinase.
The overexpression of the aurora-A kinases associated with
centrosome ampli¢cation has been found in many tumours
[1,2,18]. The main reason is the presence of the STK15 gene
encoding aurora-A in the 20q13 amplicon that is at the origin
of the overexpression of the kinase. But in some tumours
although the amplicon is not present, an overactivity of the
kinase is still associated with the cancer state of the cell [2]. It
seems that in normal cell cycle, aurora-A has to be reset to co-
ordinate nuclear cycle and centrosome cycle by the same
mechanism, presumably at the restriction point in G1 when
the cell decides to duplicate both its DNA and centrosome
[19^21]. Di¡erent hypotheses might explain the phenomenon,
an over-transcription of the gene, an over-translation of the
mRNA, an abnormal stability of the mRNA or an abnormal
stability of the protein. In this last case the understanding of
the mechanisms that control aurora-A degradation is of ¢rst
importance. Those controls might not only concern aurora-A
but also the other aurora kinases. Indeed aurora-A, aurora-B
and aurora-C have been found overexpressed in cancer cells
[22].
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